147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
Download
More posts

Method for pronosis and treating a patient suffering from cancer

Complement components form a plasma innate immune cascade but could also serve as multitasking proteins, as they have functions beyond this system. […]

Method to treat and stratificate a patient sufferingfrom a cancer

The present invention relates to the stratification and treatment of patients suffering of cancer. Due to the fact that anti-PD1 therapy targets […]

Method for predicting survival time in patients suffering from cancer

The inventors found that metabolic gene signatures of human pan-tumor associated myeloid cells correlate with patient survival and cancer cell mitotic […]

New biomarker for stratifying cancer patients for immune checkpoint

The present invention relates to use of soluble CD27 as a biomarker to predict the reponse to an immune checkpoint inhibitor treatment. Inventors have […]

New biomarkers and targets for prognosis in patients with renal cell

Renal Cell Carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and has a worldwide mortality. […]

Pd-1 and tim-3 expression as biomarkers for predicting survival time

Kidney cancer also called 'renal cancer,' or ' renal cell carcinoma' (RCC) refers to cancer that has arisen from the kidney, and is by far the most […]

Follicular b cell, cd8+ t cell, treg and dendritic cell density for

Lung cancer is the most common cause of cancer related death in the world. Approximately 80% to 90% of cases involve Non–Small-Cell Lung Cancer […]

Methods and pharmaceutical compositions for the treatment of cancers

The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the […]

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr